학술논문
Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial
Document Type
Article
Author
Labori, Knut Jørgen; Bratlie, Svein Olav; Andersson, Bodil; Angelsen, Jon-Helge; Biörserud, Christina; Björnsson, Bergthor; Bringeland, Erling Audun; Elander, Nils; Garresori, Herish; Grønbech, Jon Erik; Haux, Johan; Hemmingsson, Oskar; Liljefors, Maria Gustafsson; Myklebust, Tor Åge; Nymo, Linn Såve; Peltola, Katriina; Pfeiffer, Per; Sallinen, Ville; Sandström, Per; Sparrelid, Ernesto; Stenvold, Helge; Søreide, Kjetil; Tingstedt, Bobby; Verbeke, Caroline; Öhlund, Daniel; Klint, Leif; Dueland, Svein; Lassen, Kristoffer; Aahlin, Eirik Kjus; Bratthäll, Charlotte; Halimi, Asif; Hatlevoll, Ingunn; Heby, Margareta; Kokkola, Arto; Kordes, Maximilian; Lindblad, Stina; Lundgren, Linda; Mortensen, Michael Bau; Mortensen, Kim Erlend; Persson, Jan; Rangelova, Elena; Rønne, Elin; Sandvik, Oddvar Mathias; Søreide, Jon Arne; Vilhav, Caroline; Waardal, Kim; Wennerblom, Johanna; Williamsson, Caroline; Yaqub, Sheraz
Source
The Lancet Gastroenterology & Hepatology; March 2024, Vol. 9 Issue: 3 p205-217, 13p
Subject
Language
ISSN
24681253
Abstract
In patients undergoing resection for pancreatic cancer, adjuvant modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) improves overall survival compared with alternative chemotherapy regimens. We aimed to compare the efficacy and safety of neoadjuvant FOLFIRINOX with the standard strategy of upfront surgery in patients with resectable pancreatic ductal adenocarcinoma.